Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18280241 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Yoon SO, et al. (2008) Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell 29, 362-75 18280241
Download Sites

S126-p - RANBP3 (human)
Orthologous residues
RANBP3 (human): S126‑p, RANBP3 iso2 (human): S126‑p, RANBP3 iso3 (human): S58‑p, RANBP3 (mouse): S58‑p, RANBP3 (rat): S58‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
KINASE p90RSK (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) phospho-antibody, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme
KINASE p90RSK (human) phospho-antibody, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme
KINASE RSK2 (human) phospho-antibody, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
LY294002 phorbol ester no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester no effect upon treatment-induced increase
insulin increase
Akt-I-1 insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin inhibit treatment-induced increase
LY294002, U0126 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
EGF increase
LY294002 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
LY294002, U0126 EGF inhibit treatment-induced increase
rapamycin EGF no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
RAN (human) Induces activity, induced, intracellular localization co-immunoprecipitation, chemical cross-linking
 Comments:  inhibits RCC1 activity


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.